Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J
Division of Cancer Biology and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892.
Cancer Res. 1989 Apr 1;49(7):1738-45.
B72.3 is a murine monoclonal antibody (IgG1) that recognizes a tumor-associated glycoprotein, termed TAG-72. B72.3 has been shown, using a variety of methodologies, to have a high degree of selective reactivity for colorectal, ovarian, lung, and breast carcinomas. Radiolabeled B72.3 has been administered both i.v. and i.p. in patients with colorectal and ovarian cancer as well as other carcinomas and has been shown to selectively bind to approximately 70-80% of metastatic lesions. Greater than 50% of the patients that have been treated with B72.3 have developed an immunological response to murine IgG after a single injection. In an attempt to minimize the immune response of these patients to the administered murine monoclonal antibody, we developed a recombinant form of the murine B72.3 as well as a recombinant/chimeric antibody, using the variable regions of the murine B72.3 and human heavy chain (gamma 4) and light chain (kappa) constant regions. We report here that both the recombinant B72.3 [rB72.3] and the recombinant/chimeric B72.3 [cB72.3(gamma 4)] IgGs maintain the tissue binding and idiotypic specificity of the native murine IgG. The native B72.3, rB72.3, and cB72.3(gamma 4) IgGs were radiolabeled and the biodistribution of these IgGs was studied in athymic mice bearing human colon carcinoma xenografts (LS-174T). Differences were observed between the cB72.3(gamma 4) and the native B72.3 in the percentage of injected dose/g that localized in the tumor. The somewhat lower absolute amounts of the cB72.3(gamma 4) in the tumor are mostly likely due to the observed more rapid clearance from the blood and body of the mouse as compared to the native B72.3 and rB72.3. All three forms [native B72.3, rB72.3, and cB72.3(gamma 4)] of the IgG, however, were able to localize the colon tumor with similar radiolocalization indices [percentage of injected dose/g in tumor divided by the percentage of injected dose/g in normal tissue].
B72.3是一种鼠单克隆抗体(IgG1),可识别一种称为TAG - 72的肿瘤相关糖蛋白。使用多种方法已证明,B72.3对结直肠癌、卵巢癌、肺癌和乳腺癌具有高度的选择性反应性。放射性标记的B72.3已通过静脉注射和腹腔注射给予结直肠癌、卵巢癌以及其他癌症患者,并已证明其能选择性地结合约70 - 80%的转移病灶。超过50%接受B72.3治疗的患者在单次注射后对鼠IgG产生了免疫反应。为尽量减少这些患者对所给予的鼠单克隆抗体的免疫反应,我们利用鼠B72.3的可变区以及人重链(γ4)和轻链(κ)恒定区,开发了鼠B72.3的重组形式以及重组/嵌合抗体。我们在此报告,重组B72.3[rB72.3]和重组/嵌合B72.3[cB72.3(γ4)]IgG均保持了天然鼠IgG的组织结合和独特型特异性。对天然B72.3、rB72.3和cB72.3(γ4)IgG进行放射性标记,并在携带人结肠癌异种移植瘤(LS - 174T)的无胸腺小鼠中研究了这些IgG的生物分布。在肿瘤中定位的注射剂量/克百分比方面,观察到cB72.3(γ4)与天然B72.3之间存在差异。与天然B72.3和rB72.3相比,肿瘤中cB72.3(γ4)的绝对量略低很可能是由于观察到其从小鼠血液和体内清除更快。然而,所有三种形式的IgG[天然B72.3、rB72.3和cB72.3(γ4)]都能够以相似的放射性定位指数[肿瘤中注射剂量/克百分比除以正常组织中注射剂量/克百分比]定位结肠肿瘤。